FREMONT, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Vermillion, Inc. , a molecular diagnostics company, today announced William C. Wallen, Ph.D. Chief Scientific Officer, Senior Vice President, Research and Development for IDEXX Laboratories, will be joining its board of directors upon confirmation of Vermillion’s bankruptcy plan.
Prior to joining IDEXX Laboratories, Dr. Wallen held a number of high level positions with Bayer Healthcare, Diagnostics Division achieving the position of Senior Vice President, Head Officer of Technology. He previously held leadership roles at Becton Dickenson and Wampole Laboratories, a division of Carter-Wallace, Inc. Dr. Wallen received his Bachelor and Masters of Science from Michigan State University and his Ph.D. in Molecular Biology from University of Arizona College of Medicine.
“We are thrilled that someone with Dr. Wallen’s stature and expertise has selected Vermillion to be the company on whose Board he wishes to sit,” said Page.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women’s health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at www.vermillion.com.
The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers -- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
Forward-Looking Statements
CONTACT: Jill Totenberg, The Totenberg Group, +1-212-994-7363, or
+1-917-697-6900, jt@totenberggroup.com
Web site: http://www.vermillion.com/
